Beneficial effects of melatonin in a rat model of sporadic Alzheimer’s disease

Biogerontology

Volumn 16, Issue 3, 2015, Pages 303-316

  Rudnitskaya, Ekaterina A ^a   Maksimova, Kseniya Yi ^b   Muraleva, Natalia A ^a   Logvinov, Sergey V ^b   Yanshole, Lyudmila V ^c,d   Kolosova, Nataliya G ^a,d,e   Stefanova, Natalia A ^a  

^a INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^b SIBERIAN STATE MEDICAL UNIVERSITY   (Russian Federation)

^c INTERNATIONAL TOMOGRAPHY CENTER   (Russian Federation)

^d NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

^e Institute of Mitoengineering   (Russian Federation)

Author keywords

Alzheimer s disease; Melatonin; Neurodegeneration; OXYS rats

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; GROWTH HORMONE; MELATONIN; SOMATOMEDIN; SOMATOMEDIN C;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ELEVATED PLUS MAZE TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR; GROWTH HORMONE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; LOCOMOTION; MALE; NERVE DEGENERATION; NONHUMAN; OPEN FIELD TEST; PINEAL BODY; PRIORITY JOURNAL; RAT; REFERENCE MEMORY; SENESCENCE; AGING, PREMATURE; ANIMAL; ANIMAL BEHAVIOR; BLOOD; COGNITION; DISEASE MODEL; DRUG EFFECTS; MAZE TEST; METABOLISM; MUTANT RAT STRAIN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ADMINISTRATION, ORAL; AGING, PREMATURE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION; DISEASE MODELS, ANIMAL; GROWTH HORMONE; HIPPOCAMPUS; INSULIN-LIKE GROWTH FACTOR I; LOCOMOTION; MALE; MAZE LEARNING; MELATONIN; PINEAL GLAND; RATS; RATS, MUTANT STRAINS; RATS, WISTAR;

EID: 84938414709     PISSN: 13895729     EISSN: 15736768     Source Type: Journal    
DOI: 10.1007/s10522-014-9547-7     Document Type: Article

References (25)

1. Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK (2013) GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Therapeut 138:155–175
2. Andersen P, Morris R, Amaral D, Bliss T, O’Kneefe J (2007) The Hippocampus Book. Oxford University Press, Inc., New York
3. Bubenik GA, Konturek SJ (2011) Melatonin and aging: prospects for human treatment. J Physiol Pharmacol 62:13–19
4. Castellano JM, Deane R, Gottesdiener AJ, Verghese PhB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM (2012) Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc Natl Acad Sci USA 109:15502–15507
5. Durany N, Michel T, Kurt J, Cruz-Sánchez FF, Cervás-Navarro J, Reiderer P (2000) Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer’s disease brains. Int J Dev Neurosci 18:807–813
6. Esposito E, Cuzzocrea S (2010) Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 8:228–242
7. Hardeland R (2012) Melatonin in aging and disease—multiple consequences of reduced secretion, options and limits of treatment. Aging Dis 3:194–225
8. Jenwitheesuk A, Nopparat C, Mukda S, Wongchitrat P, Govitrapong P (2014) Melatonin regulates aging and neurodegeneration through energy metabolism, epigenetics, autophagy and circadian rhythm pathways. Int J Mol Sci 15:16848–16884
9. Kolosova NG, Stefanova NA, Muraleva NA, Skulachev VP (2012) The mitochondria-targeted antioxidant SkQ1 but not N-acetylcysteine reverses aging-related biomarkers in rats. Aging (Albany NY) 4:686–694
10. Kozhevnikova OS, Korbolina EE, Stefanova NA, Muraleva NA, Orlov YL, Kolosova NG (2013) Association of AMD-like retinopathy development with an Alzheimer’s disease metabolic pathway in OXYS rats. Biogerontology 14:753–762
11. Lin L, Huang QX, Yang SS, Chu J, Wang JZ, Tian Q (2013) Melatonin in Alzheimer’s disease. Int J Mol Sci 14:14575–14593
12. Moodly KK, Chan D (2014) The hippocampus in neurodegenerative disease. Front Neurol Neurosci 34:95–108
13. Nyberg F, Hallberg M (2013) Growth hormone and cognitive function. Nat Rev Endocrinol 9:357–365
14. Paxinos G, Watson CH (2007) The rat brain in stereotaxic coordinates, 6th edn. Elsevier, Sydney
15. Ramírez-Rodríguez G, Klempin F, Babu H, Benítez-King G, Kempermann G (2009) Melatonin modulates cell survival of new neurons in the hippocampus of adult mice. Neuropsychopharmacology 34:2180–2191
16. Reichardt LF (2006) Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 361:1545–1564
17. Sardi F, Fassina L, Venturini L, Inguscio M, Guerriero F, Rolfo E, Ricevuti G (2011) Alzheimer’s disease, autoimmunity and inflammation. The good, the bad and the ugly. Autoimmun Rev 11:149–153
18. Shcheglova TV, Amstislavskaya TG, Kolosova NG (2002) Serotonin metabolism in the brain structures of prematurely ageing OXYS rats. Neurochemistry 19:269–273
19. Snytnikova OA, Tsentalovich YP, Stefanova NA, Fursova AZh, Kaptein R, Sagdeev RZ, Kolosova NG (2012) The therapeutic effect of mitochondria-targeted antioxidant SkQ1 and Cistanche deserticola is associated with increased levels of tryptophan and kynurenine in the rat lenses. Dokl Biochem Biophys 447:300–303
20. Stefanova NA, Fursova AZh, Kolosova NG (2010) Behavioral effects induced by mitochondria-targeted antioxidant SkQ1 in Wistar and senescence-accelerated OXYS rats. J Alzheimers Dis 21:479–491
21. Stefanova NA, Fursova AZh, Sarsenbaev KN, Kolosova NG (2011) Effects of Cistanche deserticola on behavior and signs of cataract and retinopathy in senescence-accelerated OXYS rats. J Ethnopharmacol 138:624–632
22. Stefanova NA, Kozhevnikova OS, Vitovtov AO, Maksimova KYi, Logvinov SV, Rudnitskaya EA, Korbolina EE, Muraleva NA, Kolosova NG (2014a) Senescence-accelerated OXYS rats: a model of age-related cognitive decline with relevance to abnormalities in Alzheimer disease. Cell Cycle 13:1–12
23. Stefanova NA, Muraleva NA, Skulachev VP, Kolosova NG (2014b) Alzheimer’s disease-like pathology in senescence-accelerated OXYS rats can be partially retarded with mitochondria-targeted antioxidant SkQ1. J Alzheimers Dis 38:681–694
24. Wu YH, Swaab DF (2007) Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer’s disease. Sleep Med 8:623–636
25. Yanshole VV, Snytnikova OA, Kiryutin AS, Yanshole LV, Sagdeev RZ, Tsentalovich YP (2014) Metabolomics of the rat lens: a combined LC–MS and NMR study. Exp Eye Res 125:71–78